# Sertraline Versus Escitalopram in South Asian Participants With Moderate to Severe Major Depressive Disorder

> **NCT05950061** · PHASE3 · COMPLETED · sponsor: **KRL Hospital, Islamabad** · enrollment: 744 (actual)

## Conditions studied

- Major Depressive Disorder

## Interventions

- **DRUG:** Sertraline
- **DRUG:** Escitalopram

## Key facts

- **NCT ID:** NCT05950061
- **Lead sponsor:** KRL Hospital, Islamabad
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-06-01
- **Primary completion:** 2022-10-29
- **Final completion:** 2023-02-26
- **Target enrollment:** 744 (ACTUAL)
- **Last updated:** 2023-07-18

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05950061

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05950061, "Sertraline Versus Escitalopram in South Asian Participants With Moderate to Severe Major Depressive Disorder". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05950061. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*